Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0F5AQ
|
||||
| Former ID |
DNC010967
|
||||
| Drug Name |
5-(2-phenethylpiperazin-1-yl)-1H-indazole
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [551240] | ||
| Formula |
C19H22N4
|
||||
| Canonical SMILES |
C1CN(C(CN1)CCC2=CC=CC=C2)C3=CC4=C(C=C3)NN=C4
|
||||
| InChI |
1S/C19H22N4/c1-2-4-15(5-3-1)6-7-18-14-20-10-11-23(18)17-8-9-19-16(12-17)13-21-22-19/h1-5,8-9,12-13,18,20H,6-7,10-11,14H2,(H,21,22)
|
||||
| InChIKey |
OOXRIQOVBUMMQG-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Cytochrome P450 3A4 | Target Info | Inhibitor | [551240] | |
| PathWhiz Pathway | Caffeine Metabolism | ||||
| Retinol Metabolism | |||||
| WikiPathways | Metapathway biotransformation | ||||
| Aflatoxin B1 metabolism | |||||
| Estrogen metabolism | |||||
| Benzo(a)pyrene metabolism | |||||
| Tamoxifen metabolism | |||||
| Tryptophan metabolism | |||||
| Oxidation by Cytochrome P450 | |||||
| Nuclear Receptors in Lipid Metabolism and Toxicity | |||||
| Nuclear Receptors Meta-Pathway | |||||
| Farnesoid X Receptor Pathway | |||||
| Vitamin D Receptor Pathway | |||||
| Felbamate Metabolism | |||||
| Lidocaine metabolism | |||||
| Nifedipine Activity | |||||
| Colchicine Metabolic Pathway | |||||
| Irinotecan Pathway | |||||
| Drug Induction of Bile Acid Pathway | |||||
| Fatty Acid Omega Oxidation | |||||
| Codeine and Morphine Metabolism | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.